Also, targeting both Aβ and tau, not only Aβ, by passive immunotherapy was able to ameliorate cognitive deficits in a 3×Tg AD animal model (Oddo et al. 2006, 2004). This evidence concerns the gene MAPT and Alzheimer disease.